Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (291-300 of 303) with videos related to

Pageof 31
Sort By:
Nature Structural & Molecular Biology|December 23, 2015
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designJason Gorman, Cinque Soto, Max M Yang, et al.
Plos Pathogens|June 29, 2023
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsNonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, et al.
Science Immunology|August 8, 2017
Potent and broad HIV-neutralizing antibodies in memory B cells and plasmaLaTonya D Williams, Gilad Ofek, Sebastian Schätzle, et al.
Nature Medicine|August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionPeter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Ebiomedicine|June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionKelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Science Translational Medicine|March 17, 2017
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodiesMattia Bonsignori, Edward F Kreider, Daniela Fera, et al.
The New England Journal of Medicine|March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Peter B Gilbert, Michal Juraska, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention TrialsCarolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Pageof 31

Showing results (291-300 of 303) with videos related to

Sort By:
Pageof 31
Nature Structural & Molecular Biology|December 23, 2015
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designJason Gorman, Cinque Soto, Max M Yang, et al.
Plos Pathogens|June 29, 2023
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsNonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, et al.
Science Immunology|August 8, 2017
Potent and broad HIV-neutralizing antibodies in memory B cells and plasmaLaTonya D Williams, Gilad Ofek, Sebastian Schätzle, et al.
Nature Medicine|August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionPeter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Ebiomedicine|June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionKelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Science Translational Medicine|March 17, 2017
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodiesMattia Bonsignori, Edward F Kreider, Daniela Fera, et al.
The New England Journal of Medicine|March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Peter B Gilbert, Michal Juraska, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention TrialsCarolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Pageof 31